Literature DB >> 17341555

Dose-response effects of free fatty acids on glucose and lipid metabolism during somatostatin blockade of growth hormone and insulin in humans.

L C Gormsen1, N Jessen, J Gjedsted, S Gjedde, H Nørrelund, S Lund, J S Christiansen, S Nielsen, O Schmitz, N Møller.   

Abstract

CONTEXT: GH and other stress hormones stimulate lipolysis, which may result in free fatty acid (FFA)-mediated insulin resistance. However, there are also indications that FFAs in the very low physiological range have the same effect.
OBJECTIVE: The objective of the study was to address systematically the dose-response relations between FFAs and insulin sensitivity.
DESIGN: We therefore examined eight healthy men for 8 h (6 h basal and 2 h glucose clamp) on four occasions. INTERVENTION: Intralipid was infused at varying rates (0, 3, 6, 12 microl.kg(-1).min(-1)); lipolysis was blocked by acipimox; and endogenous GH, insulin, and glucagon secretion was blocked by somatostatin and subsequently replaced at fixed rates.
RESULTS: This resulted in four different FFA levels between 50 and 2000 micromol/liter, with comparable levels of insulin and counterregulatory hormones. Both in the basal state and during insulin stimulation, we saw progressively decreased glucose disposal, nonoxidative glucose disposal, and forearm muscle glucose uptake at FFA levels above 500 micromol/liter. Apart from forearm glucose uptake, the very same parameters were decreased at low FFA levels (approximately 50 micromol/liter). FFA rate of disposal was linearly related to the level of FFAs, whereas lipid oxidation reached a maximum at FFA levels approximately 1000 micromol/liter.
CONCLUSION: In the presence of comparable levels of all major metabolic hormones, insulin sensitivity peaks at physiological levels of FFAs with a gradual decrease at elevated as well as suppressed FFA concentrations. These data constitute comprehensive dose-response curves for FFAs in the full physiological range from close to zero to above 2000 micromol/liter.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17341555     DOI: 10.1210/jc.2006-2659

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  Effects of growth hormone and free fatty acids on insulin sensitivity in patients with type 1 diabetes.

Authors:  Burak Salgin; Maria L Marcovecchio; Rachel M Williams; Sarah J Jackson; Leslie J Bluck; Sandy M Humphreys; Carlo L Acerini; David B Dunger
Journal:  J Clin Endocrinol Metab       Date:  2009-06-30       Impact factor: 5.958

2.  Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.

Authors:  Esben Thyssen Vestergaard; Simon Lebech Cichosz; Niels Møller; Jens Otto Lunde Jørgensen; Jesper Fleischer
Journal:  Br J Clin Pharmacol       Date:  2017-08-24       Impact factor: 4.335

3.  Short-term sprint interval training increases insulin sensitivity in healthy adults but does not affect the thermogenic response to beta-adrenergic stimulation.

Authors:  Jennifer C Richards; Tyler K Johnson; Jessica N Kuzma; Mark C Lonac; Melani M Schweder; Wyatt F Voyles; Christopher Bell
Journal:  J Physiol       Date:  2010-06-14       Impact factor: 5.182

4.  Pulsatile changes in free fatty acids augment hepatic glucose production and preserves peripheral glucose homeostasis.

Authors:  Isabel R Hsu; Edward Zuniga; Richard N Bergman
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-04-27       Impact factor: 4.310

5.  Alterations in 3-Hydroxyisobutyrate and FGF21 Metabolism Are Associated With Protein Ingestion-Induced Insulin Resistance.

Authors:  Lydia-Ann L S Harris; Gordon I Smith; Bruce W Patterson; Raja S Ramaswamy; Adewole L Okunade; Shannon C Kelly; Lane C Porter; Samuel Klein; Jun Yoshino; Bettina Mittendorfer
Journal:  Diabetes       Date:  2017-05-04       Impact factor: 9.461

6.  Metabolic effects of insulin in a human model of ketoacidosis combining exposure to lipopolysaccharide and insulin deficiency: a randomised, controlled, crossover study in individuals with type 1 diabetes.

Authors:  Mads V Svart; Nikolaj Rittig; Ulla Kampmann; Thomas S Voss; Niels Møller; Niels Jessen
Journal:  Diabetologia       Date:  2017-04-07       Impact factor: 10.122

Review 7.  Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.

Authors:  Helen Vosper
Journal:  Br J Pharmacol       Date:  2009-07-20       Impact factor: 8.739

8.  Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects.

Authors:  Louise Moller; Helene Norrelund; Niels Jessen; Allan Flyvbjerg; Steen B Pedersen; Bruce D Gaylinn; Jianhua Liu; Michael O Thorner; Niels Moller; Jens Otto Lunde Jorgensen
Journal:  J Clin Endocrinol Metab       Date:  2009-10-09       Impact factor: 5.958

9.  Glucagon-mediated impairments in hepatic and peripheral tissue nutrient disposal are not aggravated by increased lipid availability.

Authors:  Sheng-Song Chen; Tammy S Santomango; Phillip E Williams; D Brooks Lacy; Owen P McGuinness
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-02-10       Impact factor: 4.310

10.  Sustained AS160 and TBC1D1 phosphorylations in human skeletal muscle 30 min after a single bout of exercise.

Authors:  M H Vendelbo; A B Møller; J T Treebak; L C Gormsen; L J Goodyear; J F P Wojtaszewski; J O L Jørgensen; N Møller; N Jessen
Journal:  J Appl Physiol (1985)       Date:  2014-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.